EP3529260A4 - Vaccine constructs and uses thereof against staphylococcus infections - Google Patents
Vaccine constructs and uses thereof against staphylococcus infections Download PDFInfo
- Publication number
- EP3529260A4 EP3529260A4 EP17863203.0A EP17863203A EP3529260A4 EP 3529260 A4 EP3529260 A4 EP 3529260A4 EP 17863203 A EP17863203 A EP 17863203A EP 3529260 A4 EP3529260 A4 EP 3529260A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- against staphylococcus
- vaccine constructs
- staphylococcus infections
- infections
- vaccine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662411120P | 2016-10-21 | 2016-10-21 | |
| PCT/CA2017/051253 WO2018072031A1 (en) | 2016-10-21 | 2017-10-20 | Vaccine constructs and uses thereof against staphylococcus infections |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP3529260A1 EP3529260A1 (en) | 2019-08-28 |
| EP3529260A4 true EP3529260A4 (en) | 2020-12-16 |
Family
ID=62018642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP17863203.0A Pending EP3529260A4 (en) | 2016-10-21 | 2017-10-20 | Vaccine constructs and uses thereof against staphylococcus infections |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US11324815B2 (en) |
| EP (1) | EP3529260A4 (en) |
| JP (2) | JP7181208B2 (en) |
| KR (1) | KR20190082229A (en) |
| CN (1) | CN109843910A (en) |
| AR (1) | AR109847A1 (en) |
| AU (2) | AU2017346974B2 (en) |
| BR (1) | BR112019007796A2 (en) |
| CA (1) | CA3037070A1 (en) |
| CL (1) | CL2019001048A1 (en) |
| CO (1) | CO2019005169A2 (en) |
| CR (1) | CR20190249A (en) |
| DO (1) | DOP2019000102A (en) |
| IL (1) | IL265869A (en) |
| MX (2) | MX2019004539A (en) |
| MY (1) | MY195369A (en) |
| NZ (1) | NZ751880A (en) |
| PE (1) | PE20191320A1 (en) |
| PH (1) | PH12019500843A1 (en) |
| RU (2) | RU2766354C2 (en) |
| SG (2) | SG10201912431XA (en) |
| TW (1) | TW201819402A (en) |
| UY (1) | UY37448A (en) |
| WO (1) | WO2018072031A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220185852A1 (en) * | 2020-12-11 | 2022-06-16 | Bayer Animal Health Gmbh | Methods and compositions for improved production of an antigen for use in an s. aureus vaccine |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120034258A1 (en) * | 2009-03-23 | 2012-02-09 | Herron-Olson Lisa L | Polypeptides and immunizing compounds containing gram positive polypeptides and methods of use |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1288774C (en) | 1985-01-07 | 1991-09-10 | Deborah A. Eppstein | 1,2-dialkoxy-w-trialkylammonium cationic surfactants |
| US6228844B1 (en) | 1991-11-12 | 2001-05-08 | Vical Incorporated | Stimulating vascular growth by administration of DNA sequences encoding VEGF |
| US7060458B1 (en) | 1997-08-14 | 2006-06-13 | Wyeth | Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics |
| US6380370B1 (en) | 1997-08-14 | 2002-04-30 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics |
| US6833134B2 (en) | 2000-06-12 | 2004-12-21 | University Of Saskacthewan | Immunization of dairy cattle with GapC protein against Streptococcus infection |
| GB0107661D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Staphylococcus aureus |
| PL229487B1 (en) | 2002-11-12 | 2018-07-31 | Brigham & Womens Hospital Inc | Polysaccharide vaccine for staphylococcal infections |
| CN1569893A (en) | 2003-07-21 | 2005-01-26 | 中国人民解放军军事医学科学院基础医学研究所 | Antigen epitope of gold staphylococcus virulence factor regulatory protein and its mimic epitope and use thereof |
| RU2419628C2 (en) | 2004-09-22 | 2011-05-27 | ГлаксоСмитКлайн Байолоджикалз с.а. | Immunogenic composition for use in vaccination against staphylococci |
| AU2005333603A1 (en) * | 2004-10-21 | 2007-01-04 | Wyeth | Immunogenic compositions of Staphylococcus epidermidis polypeptide antigens |
| KR100729954B1 (en) | 2004-12-01 | 2007-06-20 | 주식회사 엘지생명과학 | Formulation of SEC1 Mutated Protein and Method for Formulation of the Same |
| WO2008152447A2 (en) | 2006-10-30 | 2008-12-18 | The University Of Western Ontario | Staphylococcus aureus specific anti-infectives |
| NZ612315A (en) * | 2009-04-14 | 2014-10-31 | Novartis Ag | Compositions for immunising against staphylococcus aureus |
| PT2547361T (en) | 2010-03-17 | 2020-12-07 | Socpra Sciences Et Genie Sec | Bacterial vaccine components from staphylococcus aureus and uses thereof |
| MX340446B (en) | 2011-06-19 | 2016-07-08 | Univ New York | Methods of treating and preventing staphylococcus aureus infections and associated conditions. |
-
2017
- 2017-10-20 NZ NZ751880A patent/NZ751880A/en unknown
- 2017-10-20 AR ARP170102922A patent/AR109847A1/en unknown
- 2017-10-20 US US16/337,457 patent/US11324815B2/en active Active
- 2017-10-20 KR KR1020197014191A patent/KR20190082229A/en active IP Right Grant
- 2017-10-20 WO PCT/CA2017/051253 patent/WO2018072031A1/en unknown
- 2017-10-20 AU AU2017346974A patent/AU2017346974B2/en not_active Ceased
- 2017-10-20 MX MX2019004539A patent/MX2019004539A/en unknown
- 2017-10-20 CA CA3037070A patent/CA3037070A1/en active Pending
- 2017-10-20 RU RU2019115303A patent/RU2766354C2/en active
- 2017-10-20 SG SG10201912431XA patent/SG10201912431XA/en unknown
- 2017-10-20 JP JP2019542759A patent/JP7181208B2/en active Active
- 2017-10-20 PE PE2019000844A patent/PE20191320A1/en unknown
- 2017-10-20 CN CN201780064991.1A patent/CN109843910A/en active Pending
- 2017-10-20 MY MYPI2019002159A patent/MY195369A/en unknown
- 2017-10-20 CR CR20190249A patent/CR20190249A/en unknown
- 2017-10-20 UY UY0001037448A patent/UY37448A/en unknown
- 2017-10-20 TW TW106136089A patent/TW201819402A/en unknown
- 2017-10-20 EP EP17863203.0A patent/EP3529260A4/en active Pending
- 2017-10-20 BR BR112019007796A patent/BR112019007796A2/en unknown
- 2017-10-20 RU RU2022100889A patent/RU2022100889A/en unknown
- 2017-10-20 SG SG11201901483QA patent/SG11201901483QA/en unknown
-
2019
- 2019-04-07 IL IL265869A patent/IL265869A/en unknown
- 2019-04-16 PH PH12019500843A patent/PH12019500843A1/en unknown
- 2019-04-17 CL CL2019001048A patent/CL2019001048A1/en unknown
- 2019-04-17 DO DO2019000102A patent/DOP2019000102A/en unknown
- 2019-04-17 MX MX2023001219A patent/MX2023001219A/en unknown
- 2019-05-21 CO CONC2019/0005169A patent/CO2019005169A2/en unknown
-
2022
- 2022-04-05 US US17/713,683 patent/US20220288183A1/en active Pending
- 2022-06-28 AU AU2022204585A patent/AU2022204585A1/en not_active Abandoned
- 2022-11-16 JP JP2022183528A patent/JP2023025066A/en not_active Withdrawn
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120034258A1 (en) * | 2009-03-23 | 2012-02-09 | Herron-Olson Lisa L | Polypeptides and immunizing compounds containing gram positive polypeptides and methods of use |
Non-Patent Citations (4)
| Title |
|---|
| CHANG B S ET AL: "Protective effects of recombinant staphylococcal enterotoxin type C mutant vaccine against experimental bovine infection by a strain of Staphylococcus aureus isolated from subclinical mastitis in dairy cattle", VACCINE, ELSEVIER, AMSTERDAM, NL, vol. 26, no. 17, 16 April 2008 (2008-04-16), pages 2081 - 2091, XP022590858, ISSN: 0264-410X, [retrieved on 20080314], DOI: 10.1016/J.VACCINE.2008.02.043 * |
| DATABASE UniProt [online] 16 September 2015 (2015-09-16), "SubName: Full=Probable HMG-CoA synthase {ECO:0000313|EMBL:BAB41253.1};", retrieved from EBI accession no. UNIPROT:A0A0H3JK22 Database accession no. A0A0H3JK22 * |
| GILL STEVEN R ET AL: "Insights on evolution of virulence and resistance from the complete genome analysis of an early methicillin-resistant Staphylococcus aureus strain and a biofilm-producing methicillin-resistant Staphylococcus epidermidis strain", JOURNAL OF BACTERIOLOGY,, vol. 187, no. 7, 1 April 2005 (2005-04-01), pages 2426 - 2438, XP002463146, ISSN: 0021-9193, DOI: 10.1128/JB.187.7.2426-2438.2005 * |
| KURODA M ET AL: "Whole genome sequencing of meticillin-resistant Staphylococcus aureus", THE LANCET, ELSEVIER, AMSTERDAM, NL, vol. 357, no. 9264, 21 April 2001 (2001-04-21), pages 1225 - 1240, XP004806262, ISSN: 0140-6736, DOI: 10.1016/S0140-6736(00)04403-2 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3529279A4 (en) | Cd133-binding agents and uses thereof | |
| EP3148576B8 (en) | Vaccine composition against streptococcus suis infection | |
| EP3419676A4 (en) | Antimicrobial compositions and uses thereof | |
| EP3255059A4 (en) | Antimicrobial peptide wy-21 and use thereof | |
| EP3118206A4 (en) | Sixteen-membered macrolide compound and applications thereof | |
| EP3511407A4 (en) | Christensenella intestinihominis and application thereof | |
| EP3096616A4 (en) | Dermaseptin-type and piscidin-type antimicrobial peptides | |
| EP3273989A4 (en) | Streptococcal vaccine | |
| EP3454908A4 (en) | Targeted constructs and formulations thereof | |
| EP3426255A4 (en) | Antibacterial compounds and uses thereof | |
| EP3191114A4 (en) | Occidiofungin formulations and uses thereof | |
| EP3423076A4 (en) | Topical cyclosporine-containing formulations and uses thereof | |
| EP3476932A4 (en) | Novel sporichthyaceae microorganism and use thereof | |
| EP3145549A4 (en) | Topical formulations and uses thereof | |
| EP3522907A4 (en) | Targeted effector proteins and uses thereof | |
| EP3691629A4 (en) | Nutrient-spore formulations and uses thereof | |
| EP3554944B8 (en) | Insect elimination system and use thereof | |
| EP3406591A4 (en) | Dicaffeoyl-spermidine derivative glycoside and use thereof | |
| EP3378870A4 (en) | Novel antimicrobial peptide and use thereof | |
| EP3299459A4 (en) | Staphylococcus lyase and use thereof | |
| EP3638297A4 (en) | Bacterial vaccine | |
| EP3500288A4 (en) | Antimicrobial peptides and uses thereof | |
| EP3439693A4 (en) | Novel pneumococcal vaccine formulations | |
| EP3360886A4 (en) | Foxm1-derived peptide, and vaccine including same | |
| IL265869A (en) | Vaccine constructs and uses thereof against staphylococcus infections |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20190430 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: BA ME |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 39/085 20060101ALI20200810BHEP Ipc: C12N 15/31 20060101ALI20200810BHEP Ipc: C07K 19/00 20060101ALI20200810BHEP Ipc: A61P 37/04 20060101ALI20200810BHEP Ipc: C07K 14/31 20060101AFI20200810BHEP Ipc: A61P 31/04 20060101ALI20200810BHEP Ipc: C12N 15/62 20060101ALI20200810BHEP Ipc: C12N 15/63 20060101ALI20200810BHEP Ipc: C12N 1/21 20060101ALI20200810BHEP |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20201118 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 31/04 20060101ALI20201112BHEP Ipc: C07K 19/00 20060101ALI20201112BHEP Ipc: C07K 14/31 20060101AFI20201112BHEP Ipc: A61P 37/04 20060101ALI20201112BHEP Ipc: C12N 15/62 20060101ALI20201112BHEP Ipc: C12N 15/63 20060101ALI20201112BHEP Ipc: C12N 1/21 20060101ALI20201112BHEP Ipc: A61K 39/085 20060101ALI20201112BHEP Ipc: C12N 15/31 20060101ALI20201112BHEP |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| 17Q | First examination report despatched |
Effective date: 20211004 |